INS and type 2 diabetes mellitus: To address this evidence gap, our research team has initiated a randomized, controlled, open-label clinical trial aimed at systematically evaluating the efficacy of the GLP-1RA exenatide (administered via injection) versus premixed insulin (NovoRapid 30) in inducing clinical remission among treatment-naive patients with overweight or obese T2DM.